© 2025 HSP News Service, L.L.C.
In an analysis of the phase III PROfound trial reported in the Journal of Clinical Oncology, Joaquin Mateo, MD, PhD, and colleagues found that olaparib improved outcomes vs abiraterone or enzalutamide among the subgroup of patients with metastatic castration-resistant prostate cancer who had...
In a phase I study reported in the Journal of Clinical Oncology, Scott T. Tagawa, MD, MS, FASCO, FACP, and colleagues determined the recommended phase II dose and described preliminary activity of actinium-225–J591—an anti–prostate-specific membrane antigen (PSMA) monoclonal antibody (J591)...
As reported in The Lancet Oncology by Fred Saad, MD, of the Centre Hospitalier de l’Université de Montréal, and colleagues, the final prespecified overall survival analysis of the phase III PROpel trial has shown no significant benefit with the addition of first-line olaparib to abiraterone in...
On November 16, the U.S. Food and Drug Administration (FDA) approved the androgen receptor inhibitor enzalutamide (Xtandi) for patients with nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis. EMBARK Trial Efficacy was evaluated in EMBARK...
Researchers have compiled a comprehensive list of genetic variants that may be associated with the risk of developing prostate cancer, according to a recent study published by Wang et al in Nature Genetics. The new findings included major increases in representation among patients from racial and...
Bone scans may overstage prostate cancer at initial staging compared with prostate-specific membrane antigen (PSMA) positron-emission tomography (PET), according to a recent study published by Hope et al in The Journal of Nuclear Medicine. Background PSMA PET is known to be more accurate than...
In a single-institution phase I dose-expansion trial reported in The Lancet Oncology, Aggarwal et al found that a single dose of lutetium-177–PSMA-617 (LuPSMA) followed by pembrolizumab maintenance was associated with activity in patients with metastatic castration-resistant prostate cancer. Study...
Black men in the United States are more likely to develop prostate cancer than White men, and after diagnosis, they’re more likely to have advanced disease and to die of the disease than White men. Although it would seem that earlier prostate‐specific antigen (PSA) screening would reduce the risk...
Prostate cancer treatment just got a major boost from the PACE trials, which may have established a new standard of care in low- and favorable intermediate-risk disease, according to data presented at the 2023 American Society for Radiation Oncology (ASTRO) Annual Meeting.1 The results of the phase ...
In the phase III EMBARK trial reported in The New England Journal of Medicine, Stephen J. Freedland, MD, and colleagues found that enzalutamide/leuprolide and enzalutamide alone improved metastasis-free survival vs leuprolide alone in patients with high-risk biochemical recurrence of prostate...
Data from the phase III PSMAfore trial were presented during a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2023 (Abstract LBA13). Results showed that the trial of lutetium Lu-177 vipivotide tetraxetan met its primary endpoint, with a clinically meaningful and ...
Researchers have discovered that patients with longer prostatic urethras may have an increased risk of experiencing moderate and chronic urinary side effects after receiving radiation for prostate cancer, according to a recent study published by Lee et al in Academic Radiology. The new findings...
In a study reported in JAMA Oncology, Darst et al identified germline genetic variants that were associated with increased risk of aggressive vs nonaggressive prostate cancer. As stated by the investigators, “Germline gene panel testing is recommended for men with advanced prostate cancer or a...
In an Italian phase II trial (ARTO) reported in the Journal of Clinical Oncology, Francolini et al found that the addition of stereotactic body radiation therapy (SBRT) to first-line abiraterone acetate and prednisone resulted in a significantly higher rate of biochemical response among patients...
The presence of precision medicine navigators may increase the likelihood that patients with prostate cancer, especially Black patients, will receive genomic testing that may help predict the severity of their disease and guide treatment, according to findings presented by Allen et al at the 2023...
People with intermediate-risk, localized prostate cancer may be treated as effectively using fewer and higher doses of radiation therapy delivered over five treatment sessions as they can with lower doses delivered over several weeks, a new phase III randomized trial suggested. The findings, which...
Researchers have singled out mutations in 11 genes associated with aggressive types of prostate cancer, according to a novel study published by Darst et al in JAMA Oncology. The new findings may lead to improvements in diagnosis and treatment. Background Currently, oncologists use genetic tests to...
On August 11, 2023, the fixed-dose combination of the PARP inhibitor niraparib and the CYP17 inhibitor abiraterone acetate plus prednisone was approved for patients with deleterious or suspected deleterious BRCA-mutated castration-resistant prostate cancer, as determined by a U.S. Food and Drug...
As reported by Fred Saad, MD, and colleagues in The Lancet Oncology, the final prespecified overall survival analysis of the phase III PROpel trial showed no significant benefit with the addition of first-line olaparib to abiraterone in patients with metastatic castration-resistant prostate cancer...
Bipartisan legislation that may help to eliminate financial barriers to prostate cancer screening was introduced in the U.S. Senate. Sponsored by Senators Cory Booker (D-NJ) and John Boozman (R-AR), the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act would...
It seems that exercise is good for almost everything, including prostate cancer. In fact, exercise had a positive effect on sexual function and enjoyment in men with prostate cancer, according to a recent study presented at the 2023 ASCO Breakthrough meeting by lead study author Daniel Galvão, PhD, ...
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has provided standardized guidance on the selection and management of patients receiving lutetium-177–labeled PSMA-617 (LuPSMA) radionuclide therapy for metastatic castration-resistant prostate cancer, according to a new consensus...
Researchers have found that about one-third of treatment recommendations from the artificial intelligence (AI) model ChatGPT 3.5 were nonconcordant with the NCCN Clinical Practice Guidelines in Oncology® (NCCN Guidelines®), according to a recent study published by Chen et al in JAMA Oncology. The...
In the long-term treatment phase of an Israeli phase II study reported in the journal Nutrients, Keizman et al found that PectaSol modified citrus pectin (P-MCP) may be effective in patients with nonmetastatic, biochemically relapsed prostate cancer. As stated by the investigators, “[P-MCP] is a...
In a phase II trial reported in the Journal of Clinical Oncology, Slovin et al found that concomitant abiraterone acetate plus prednisone (AAP) and cabazitaxel appeared to produce better outcomes than AAP followed by cabazitaxel upon disease progression in patients with metastatic...
In a U.S. retrospective cohort study reported in JAMA Network Open, Sebastian et al found that treatment at a high-volume radiation facility was associated with improved overall survival among men with very high–risk prostate cancer receiving curative-intent radiotherapy with androgen-deprivation...
Researchers have identified a cell metabolism process found in male patients with West African ancestry who have diabetes and metastatic prostate cancer that could potentially lead to improved testing and treatments for Black patients with both diseases. The findings by Shuck et al were presented...
Prostate-specific membrane antigen positron-emission tomography/computed tomography (PSMA PET/CT) imaging may help physicians diagnose advanced disease and select the appropriate therapeutic interventions in patients aged 80 years or older with suspected prostate cancer, according to a recent study ...
As reported in The New England Journal of Medicine by Karim Fizazi, MD, PhD, of Gustave Roussy Institute, Paris-Saclay University, and colleagues, the phase III TRITON3 trial has shown significantly improved progression-free survival with rucaparib vs physician-selected single-agent therapy in the...
The addition of the androgen receptor inhibitor darolutamide to androgen-deprivation therapy and docetaxel reduced the risk of death by 30% compared with androgen-deprivation therapy plus docetaxel in patients with metastatic hormone-sensitive prostate cancer, according to a post hoc analysis of...
The addition of the PARP (poly [ADP-ribose] polymerase) inhibitor olaparib to standard-of-care abiraterone in the first-line setting of metastatic castration-resistant prostate cancer achieved longer progression-free survival vs abiraterone alone, as demonstrated in the final results of the phase...
Presented here are summaries of three abstracts from the 2023 ASCO Annual Meeting that are pertinent for patients with metastatic castration-resistant prostate cancer. The first two focus on men with homologous recombinant repair (HRR) gene alterations, including BRCA1/2. In the first study,...
It is an exciting time in the development of new treatments for urologic cancers. There have been a number of major changes both in advanced disease and in the perioperative setting over the past year. Urothelial and Bladder Cancers In urothelial cancer, at last, we have randomized data supporting...
On August 11, the U.S. Food and Drug Administration (FDA) approved the fixed-dose combination of niraparib and abiraterone acetate (Akeega), with prednisone, for adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer, as determined by...
On June 20, 2023, the PARP inhibitor talazoparib was approved for use with enzalutamide in homologous recombination repair (HRR) gene–mutated metastatic castration-resistant prostate cancer.1 Supporting Efficacy Data Approval was based on findings in the multicohort, double-blind TALAPRO-2 trial...
Presented here are summaries of three abstracts from the 2023 ASCO Annual Meeting that are pertinent for patients with metastatic castration-resistant prostate cancer. The first two focus on men with homologous recombinant repair (HRR) gene alterations, including BRCA1/2. In the first study,...
As reported in The Lancet by Neeraj Agarwal, MD, FASCO, and colleagues, the phase III TALAPRO-2 trial has shown that the addition of talazoparib to enzalutamide improved radiographic progression–free survival vs enzalutamide alone in the first-line treatment of patients with metastatic...
A combination of resistance and aerobic exercise may improve sexual function in patients with prostate cancer, according to a new study conducted in Australia. The research was presented by Galvao et al at the 2023 ASCO Breakthrough meeting (Abstract 71) in Yokohama, Japan. “Sexual dysfunction is a ...
In a study reported in JAMA Network Open, KC et al identified factors involved with primary cancer mortality vs noncancer mortality among long-term survivors of breast, prostate, and colorectal cancers. Study Details The study included data on 627,702 patients in the Surveillance, Epidemiology,...
The use of magnetic resonance (MR)-guided daily adaptive stereotactic body radiotherapy (SBRT) might make radiation therapy safer for patients with prostate cancer than standard computed tomography (CT)-guided SBRT by helping clinicians more accurately target the prostate while avoiding nearby...
Black patients may be 1.6 times more likely to believe medical information presented by a Black speaker than information presented by a White speaker, according to a new study published by Loeb et al in JAMA Network Open. The findings highlight the importance of increasing racial diversity among...
In a systematic review and individual patient meta-analysis reported in The Lancet Oncology, Claire L. Vale, PhD, and colleagues in the STOPCAP M1 collaboration identified factors associated and not associated with improved outcomes after the addition of docetaxel to androgen-deprivation therapy...
About 50% of patients with metastatic prostate cancer may experience financial hardship as a result of their treatment, according to a new study published by Joyce et al in The Journal of Urology. Background "Our most significant finding may be that patients experience financial toxicity despite...
On May 31, 2023, the PARP inhibitor olaparib was approved by the U.S. Food and Drug Administration (FDA) with abiraterone and prednisone or prednisolone for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer, as determined by an FDA-approved companion diagnostic test.1...
Physicians may be able to personalize dosing intervals and consequently improve patient outcomes by monitoring early-response biomarkers in patients with prostate cancer who are undergoing treatment with lutetium (Lu)-177–PSMA, according to new findings presented by Emmett et al at the Society of...
In the phase III NRG Oncology/RTOG 0232 trial reported in the Journal of Clinical Oncology, Jeff M. Michalski, MD, MBA, FASTRO, and colleagues found no significant benefit in 5-year freedom from disease progression with the addition of external-beam radiation therapy (EBRT) to brachytherapy in...
As reported in the Journal of Clinical Oncology by Emmanuel S. Antonarakis, MD, and colleagues, the phase III KEYLYNK-010 trial has shown no improvement in survival outcomes with pembrolizumab/olaparib vs a next-generation hormonal agent (abiraterone or enzalutamide) in previously treated patients...
Prostate cancer is the most commonly diagnosed cancer in men in the United States and the second-leading cause of cancer death.1 It also offers a sobering example in the national conversation on racial disparities in cancer care. Despite a deeper scientific understanding of the disease—as well as ...
On June 20, the U.S. Food and Drug Administration (FDA) approved talazoparib (Talzenna) with enzalutamide for homologous recombination repair (HRR) gene–mutated metastatic castration-resistant prostate cancer. TALAPRO-2 Efficacy was evaluated in TALAPRO-2 (ClinicalTrials.gov identifier...
In an analysis from the phase III VISION trial reported in The Lancet Oncology by Karim Fizazi, MD, PhD, and colleagues, the addition of lutetium (Lu-177) vipivotide tetraxetan to standard of care was associated with improved health-related quality of life in patients with prostate-specific...